Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

Some Colorectal Cancers Are "Born To Be Bad," Have Already Spread Long Before Diagnosis

(Forbes) June 17, 2019 - Four out of five metastatic colorectal cancers have already spread before they are even diagnosed, according to new research out today, led by researchers at Stanford University.

EMA Starts Review of Leuprorelin Medicines

(ESMO) June 17, 2019 - On 14 June 2019, the European Medicines Agency (EMA) announced that its safety committee (Pharmacovigilance Risk Assessment Committee) has started a review of leuprorelin medicines after reports indicated that handling errors during preparation and administration can cause some patients to receive insufficient amounts of their medicine, thus reducing the benefits of treatment.

Pfizer Spends $11.4 Billion To Buy Array BioPharma For Its Cancer Drug Chemistry

(STAT) June 17, 2019 - Pfizer said Monday morning that it will spend $11.4 billion in cash to purchase Array BioPharma, a Boulder, Colo.-based biotech known not only for developing its own medicines but as being a top choice among biotechnology firms that need to synthesize new drugs. Pfizer said it will keep Array open as a new research site for the company. The deal values Array at $48 in cash per share. Array shares rose 60% to $47.40 in pre-market trading; Pfizer shares dipped 0.1% to $47.20.

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

(Boehringer Ingelheim) June 17, 2019 - Boehringer Ingelheim and OSE Immunotherapeutics SA today announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal antibody antagonist of SIRPα, being studied in patients with advanced solid tumors.

Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma

(Yahoo! Finance) June 15, 2019 - Forty Seven, Inc. today announced updated data from its ongoing Phase 1b/2 clinical trial evaluating 5F9 in combination with rituximab for the treatment of relapsed/refractory non-Hodgkin’s lymphoma (r/r NHL), including diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma.

CMS’ Coverage Determination For Car-T Still Delayed After A Month, And Nobody Knows Why

(MedCity News) June 14, 2019 - A legal expert said such delays from CMS are unusual. The agency said May 17 that it would delay its long-awaited national coverage determination for CAR-Ts, but since then even drugmakers haven't been given a reason or timeline.

Amgen Unveils Five-year Survival Data For Blincyto

(PharmaTimes [UK]) June 17, 2019 - Amgen has revealed “compelling” long-term survival data for its acute lymphoblastic leukemia (ALL) drug Blincyto (blinatumomab). The five-year overall survival (OS) analysis – based on data from the Phase II BLAST study, which included patients with minimal residual disease (MRD)-positive ALL – found the median OS for Blincyto-treated patients to be 36.5 months at a median follow-up of 59.8 months.

Measurable Residual Disease in AML Ups Post-HSCT Relapse Risk

(Medscape Medical News) June 14, 2019 - For patients with acute myeloid leukemia (AML), the presence of measurable residual disease (MRD) prior to bone marrow transplant significantly increases the risk for relapse among patients who receive a reduced-intensity conditioning regimen, compared to those with no MRD.

Blueprint Medicines Presents Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis at 24th EHA Congress

(Yahoo! Finance) June 15, 2019 - Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced updated data from the ongoing, registration-enabling EXPLORER trial of avapritinib in patients with systemic mastocytosis (SM).

Congress Should Take Action to Improve MACRA Implementation, Organizations Urge

(ASCO in Action) June 14, 2019 - ASCO joined more than 120 other organizations in signing on to a letter urging Congress to introduce several improvements to ensure the continued success of efforts to implement the Medicare Access and CHIP Reauthorization Act (MACRA).